Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting
Anixa Biosciences (NASDAQ: ANIX) has announced a presentation on its ovarian cancer CAR-T therapy clinical trial at the International Gynecologic Cancer Society (IGCS) 2024 Annual Global Meeting in Dublin, Ireland. The presentation, titled 'Phase I Clinical Trial of Autologous T-cells Genetically Engineered with a Chimeric Receptor to Target the Follicle Stimulating Hormone Receptor (FSHR) in Recurrent Ovarian Cancer (OVCA)', will be delivered by Dr. Robert Wenham, Chair of Gynecologic Oncology at Moffitt Cancer Center, Anixa's collaboration partner. This presentation highlights Anixa's ongoing efforts in developing innovative cancer treatments, specifically focusing on their CAR-T therapy for recurrent ovarian cancer.
Anixa Biosciences (NASDAQ: ANIX) ha annunciato una presentazione sul suo trial clinico della terapia CAR-T per il cancro ovarico durante l'Annual Global Meeting 2024 della International Gynecologic Cancer Society (IGCS) a Dublino, Irlanda. La presentazione, intitolata 'Trial Clinico di Fase I con cellule T autologhe ingegnerizzate geneticamente con un recettore chimera per colpire il recettore per l'ormone follicolo-stimolante (FSHR) nel cancro ovarico recidivante (OVCA)', sarà tenuta dal Dr. Robert Wenham, presidente di Oncologia Ginecologica presso il Moffitt Cancer Center, partner di collaborazione di Anixa. Questa presentazione mette in evidenza gli sforzi continui di Anixa nello sviluppare trattamenti innovativi per il cancro, con particolare attenzione alla loro terapia CAR-T per il cancro ovarico recidivante.
Anixa Biosciences (NASDAQ: ANIX) ha anunciado una presentación sobre su ensayo clínico de terapia CAR-T para el cáncer de ovario en la Reunión Global Anual 2024 de la International Gynecologic Cancer Society (IGCS) en Dublín, Irlanda. La presentación, titulada 'Ensayo Clínico de Fase I con células T autólogas modificadas genéticamente con un receptor quimérico para dirigir el receptor de hormona foliculoestimulante (FSHR) en cáncer de ovario recurrente (OVCA)', será presentada por el Dr. Robert Wenham, presidente de Oncología Ginecológica en el Moffitt Cancer Center, socio colaborador de Anixa. Esta presentación destaca los esfuerzos continuos de Anixa en el desarrollo de tratamientos innovadores contra el cáncer, centrándose específicamente en su terapia CAR-T para el cáncer de ovario recurrente.
아닉사 바이오사이언스 (NASDAQ: ANIX)는 아일랜드 더블린에서 열리는 국제 부인과 암 학회 (IGCS) 2024년 연례 글로벌 회의에서 난소암 CAR-T 치료제의 임상 시험에 대한 발표를 했다고 발표했습니다. 발표 제목은 '재발성 난소암 (OVCA)의 난포 자극 호르몬 수용체 (FSHR)를 표적으로 하는 유전자 변형 자가 T 세포의 1상 임상 시험'이며, 아닉사의 협력 파트너인 모피트 암 센터의 부인과 종양학 의장인 로버트 웬햄 박사가 진행합니다. 이 발표는 아닉사가 개발 중인 혁신적인 암 치료에 대한 지속적인 노력을 강조하며, 특히 재발성 난소암에 대한 CAR-T 요법에 중점을 두고 있습니다.
Anixa Biosciences (NASDAQ: ANIX) a annoncé une présentation sur son essai clinique de thérapie CAR-T pour le cancer de l'ovaire lors de la Réunion Globale Annuelle 2024 de la International Gynecologic Cancer Society (IGCS) à Dublin, en Irlande. La présentation, intitulée 'Essai Clinique de Phase I de T-cellules autologues modifiées génétiquement avec un récepteur chimérique pour cibler le récepteur de l'hormone stimulant le follicule (FSHR) dans le cancer de l'ovaire récurrent (OVCA)', sera présentée par le Dr Robert Wenham, président d'Oncologie Gynécologique au Moffitt Cancer Center, partenaire de collaboration d'Anixa. Cette présentation met en lumière les efforts continus d'Anixa pour développer des traitements innovants contre le cancer, en se concentrant spécifiquement sur leur thérapie CAR-T pour le cancer de l'ovaire récurrent.
Anixa Biosciences (NASDAQ: ANIX) hat eine Präsentation über seine CAR-T-Therapie-Studie bei Eierstockkrebs auf dem International Gynecologic Cancer Society (IGCS) 2024 Annual Global Meeting in Dublin, Irland, angekündigt. Die Präsentation mit dem Titel 'Phase I-Studie mit autologen T-Zellen, die genetisch mit einem chimären Rezeptor ausgestattet sind, um den Follikel-stimulierenden Hormonrezeptor (FSHR) bei rezidivierendem Eierstockkrebs (OVCA) anzuvisieren', wird von Dr. Robert Wenham, Vorsitzender für Gynäkologische Onkologie am Moffitt Cancer Center und Kooperationspartner von Anixa, gehalten. Diese Präsentation hebt Anixas fortwährende Bemühungen hervor, innovative Krebsbehandlungen zu entwickeln, insbesondere ihre CAR-T-Therapie für rezidivierenden Eierstockkrebs.
- Presentation of Phase I clinical trial results at a major international conference
- Collaboration with Moffitt Cancer Center, a renowned institution
- None.
The presentation, titled "Phase I Clinical Trial of Autologous T-cells Genetically Engineered with a Chimeric Receptor to Target the Follicle Stimulating Hormone Receptor (FSHR) in Recurrent Ovarian Cancer (OVCA)," will be presented by the study's principal investigator, Dr. Robert Wenham, Chair of Gynecologic Oncology at Moffitt Cancer Center, Anixa's collaboration partner.
About Anixa's CAR-T Approach (Follicle Stimulating Hormone Receptor-Mediated CAR-T technology)
Anixa's chimeric antigen receptor T-cell (CAR-T) technology approach is an autologous cell therapy comprised of engineered T-cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone (chimeric endocrine) receptor, and the target-binding domain is derived from its natural ligand, this technology is known as CER-T (chimeric endocrine receptor T-cell) therapy, a new type of CAR-T. Anixa's FSHR-mediated CAR-T technology was developed by Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine. Anixa holds an exclusive world-wide license to the technology from The Wistar Institute.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-on-its-ovarian-cancer-car-t-clinical-trial-at-the-international-gynecologic-cancer-society-2024-annual-meeting-302207803.html
SOURCE Anixa Biosciences, Inc.
FAQ
What is Anixa Biosciences presenting at the IGCS 2024 Annual Global Meeting?
Who is presenting Anixa Biosciences' (ANIX) ovarian cancer CAR-T therapy results?
When and where is the IGCS 2024 Annual Global Meeting where Anixa (ANIX) will present?
What type of cancer is Anixa Biosciences' (ANIX) CAR-T therapy targeting?
